All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
ALL HubAML HubLymphoma HubMDS HubMPN HubMultiple Myeloma

When would you use ATG vs PTCy for GvHD prophylaxis?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, When would you use ATG vs PTCy for GvHD prophylaxis?

When would you use ATG vs PTCy for GvHD prophylaxis?

In this video, Mohty discusses the use of PTCy post stem cell infusion for GvHD prophylaxis and refers to data published in 2019 in the EBMT registry that shows PTCy as potentially more effective than ATG for GvHD prophylaxis for mismatched, unrelated transplants. Mohty comments on the promising preliminary data that suggests ATG and PTCy could be combined in patients with a matched donor.